TipRanks
Go Ultimate55% OFF

MAUNA KEA TECHNOLOGIES (0P5I) AI Stock Analysis

GB:0P5I

MAUNA KEA TECHNOLOGIES

(LSE:0P5I)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue reboundThe sharp 2025 revenue rebound shows that demand for Cellvizio can recover meaningfully after a weak period. If commercial adoption and procedure activity continue improving, higher scale could support better operating leverage and strengthen the platform’s market position over the next several quarters.
Negative Factors
Deep operating lossesThe deeply negative operating margin shows that the core business is not yet covering its operating cost base, despite the revenue rebound and strong gross margin. Without sustained cost improvement or much greater scale, ongoing losses could continue consuming resources and delay a durable path to profitability.

MAUNA KEA TECHNOLOGIES (0P5I) vs. iShares MSCI United Kingdom ETF (EWC)

-50%-25%0%25%50%75%100%125%150%GB:0P5I+2.11%EWC+21.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 18.94M
Dividend Yield
―
Average Volume (3M)
1,085
Price to Earnings (P/E)
1.5
Beta (1Y)
2.19
Revenue Growth
3.38%
EPS Growth
―
Country
UK
Employees
56
Sector
General
Sector Strength
55
Industry
Medical - Devices

MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model

Company Description

Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Centr...

MAUNA KEA TECHNOLOGIES Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

GB:0P5I against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:ALERSFR:ALERS58NeutralEUR 258.39M37.573.89%―6.28%204.56%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:ALIKOFR:ALIKO46NeutralEUR 22.42M-5.20-22.03%―37.28%7.83%
FR:ALTHEFR:ALTHE46NeutralEUR 51.65M-6.76453.10%―-16.98%20.31%
FR:ALNOVFR:ALNOV45NeutralEUR 31.94M-0.76-159.70%―10.36%29.41%
FR:ALMDTFR:ALMDT43NeutralEUR 180.85M-3.00271.64%―2.16%-5.26%

* General Sector Average

Performance Comparison

0%50%100%GB:0P5IFR:ALTHEFR:ALNOVFR:ALERSFR:ALIKOFR:ALMDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
GB:0P5I and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0P5IMAUNA KEA TECHNOLOGIES0.100.001.04%
FR:ALTHETheraclion SA0.700.057.69%
FR:ALNOVNovacyt S.A.0.44-0.02-4.35%
FR:ALERSEurobio-Scientific SA26.302.158.90%
FR:ALIKOIkonisys SA1.42-0.04-2.74%
FR:ALMDTMedian Technologies3.690.7927.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.